Matthew Gallagher, 41, Los Angeles. Launched Medvi in September 2024 for $20K and two months. A telehealth service selling GLP-1 weight loss drugs — the same active ingredients as in Ozempic. Code, website, ads, and customer service were built with ChatGPT, Claude, Grok, Midjourney, Runway. Doctors, pharmacies, and delivery were handed off to partner platforms.
$401M in revenue in the first year. Two employees. 2026 forecast — $1.8B. Net margin 16.2% — three times higher than Hims & Hers with 2,400 employees. NYT verified the financials and published a profile. NYT says "one man" — though in parentheses adds "(and his brother)." Plus contract engineers, account managers, and outside agencies. But who cares when you've got a great headline.
Sam Altman texted journalists that he'd won a bet (in 2024 he predicted AI would let one person build a billion-dollar company) and wants to meet Gallagher.
That's where the story ends. What follows is what NYT barely mentions, and everyone else doesn't mention at all.
Gallagher didn't build an AI company. He built a traffic arbitrage funnel. Buys ads on Meta, drives them to a landing page, converts to a subscription — $179 for the first month, then $299 on rebill. The medical side is someone else's. The marketing is his.
What that marketing looks like: 800+ Facebook pages, each impersonating a real doctor's profile. AI-generated faces, templated posts with medical advice, links to Medvi. Target audience — women 35–55 who trust content from "doctors." One account was called "Dr. Tuckr Carlzyn MD."
Six weeks before the NYT piece, in February 2026, the FDA sent Medvi a warning letter — the site gave the impression that its drugs were FDA-approved. Medvi isn't alone — the FDA sent similar letters to 30 telehealth companies. But Medvi specifically is what NYT put on the cover as a proof of concept for the future.
OpenLoop, which handles all of Medvi's medical infrastructure, suffered a data breach in January 2026 affecting 1.6 million patients. And in November 2025, a class-action lawsuit was filed against it over oral tirzepatide tablets — plaintiffs claim there's no proven absorption mechanism. The tablet breaks down in the stomach before reaching the bloodstream.
$1.8B is not a company valuation. There's been no investment, no valuation. It's a revenue forecast. Profit — $65M a year. A decent business, but not a unicorn.
One last thing. The FDA has already determined that the semaglutide shortage is over. The legal basis for producing compounded versions is narrowing. If regulators follow through — the funnel goes to zero. The NYT article will remain.
🚫 AI unicorn
✅ AI arbitrage